Results from GALILEO-1, A First-in-Human Clinical Trial of FLT201, an AAV-Gene Therapy, in Adults with Gaucher Disease Type 1

被引：0

作者：

Goker-Alpan, Ozlem ^{[1
]}

Whittaker, Andrew ^{[2
]}

Ferrante, Francesca ^{[2
]}

机构：

[1] Lysosomal & Rare Disorders Res & Treatment Ctr, Fairfax, VA USA

[2] Freeline Therapeut, Clin Dev, Stevenage, Herts, England

来源：

MOLECULAR THERAPY | 2024年 / 32卷 / 05期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：1 / 2

页数：2

共 50 条

[1] Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease type 1
Hughes, Derralynn
Whittaker, Andrew
Ferrante, Francesca
MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
[2] Results from GALILEO-1, a first-in-human clinical trial of FLT201 gene therapy in patients with Gaucher disease Type 1
Goker-Alpan, O.
Whittaker, A.
HUMAN GENE THERAPY, 2024, 35 (3-4) : A19 - A20
[3] Design of GALILEO-1, a phase 1/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease type 1
Hughes, Derralynn A.
Barton, Sharon
Chan, Jane
Sherry, Nicole
Long, Alison
MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S57 - S58
[4] FLT201: An AAV-mediated gene therapy for type 1 Gaucher disease designed to target difficult to reach tissues
Corbau, Romuald
Miranda, Carlos
Comper, Fabrizio
Kalchev, Petya
Chisari, Elisa
Cocita, Clement
Correia, Samantha
Pandya, Jalpa
Liou, Benjamin
Northcott, Natalie
Stotter, Emmaline
Shehu, Erald
Yu, I-Mei
Khinder, Jaminder
Sheridan, Rose
Sun, Ying
Nathwani, Amit
MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S28 - S29
[5] FLT201, a Novel Investigational AAV-Mediated Gene Therapy Candidate for Gaucher Disease
Miranda, Carlos
Comper, Fabrizio
Kalcheva, Petya
Chisari, Elisa
Cocita, Clement
Correia, Samantha
Pandya, Jalpa
Liou, Benjamin
Canavese, Miriam
Northcott, Natalie
Stotter, Emmaline
Shehu, Erald
Yu, I-Mei
Khinder, Jaminder
Sheridan, Rose
Sun, Ying
Nathwani, Amit
Corbau, Romuald
MOLECULAR THERAPY, 2021, 29 (04) : 162 - 163
[6] In silico immunogenicity assessment of FLT201: an investigational gene therapy for Gaucher disease Type 1 encoding an engineered variant of the GCase enzyme
Sridharan, S.
Canavese, M.
Miranda, C. J.
Jeyakumar, J.
Kalcheva, P.
Chisari, E.
Cocita, C.
Correia, S.
Pandya, J.
Northcott, N.
Stotter, E.
Shehu, E.
Yu, I. M.
Khinder, J.
Sheridan, R.
Comper, F.
HUMAN GENE THERAPY, 2022, 33 (23-24) : A35 - A35
[7] Preliminary Results from the Phase 1/2 GuardOne Trial: A First-in-Human Study of Ex Vivo Lentiviral Gene Therapy (AVR-RD-02) in People with Gaucher Disease Type 1
Jacobsen, L. K.
Trame, M. N.
Golipour, A.
Pfeifer, R.
Khan, A.
Mason, C.
MOLECULAR THERAPY, 2021, 29 (04) : 340 - 340
[8] First-in-human study of a liver-directed AAV gene therapy (FLT190) in Fabry disease
Hughes, Derralynn A.
Patel, Niten
Kinch, Russell
Dronfield, Leanne
Short, Gerard
Sheridan, Rose
Kia, Azadeh
Jeyakumar, Jey
Corbau, Romuald
Nathwani, Amit
MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S77 - S78
[9] Development of an AAV-GBA Gene Therapy for the Treatment of Type 1 Gaucher Disease
Cheng, Ting-Wen
Souza, David
Tabet, Ricardos
Wright, Katherine
Brodfuehrer, Joanne
Keyes, Lisa
Rao-Dayton, Sheila
Lewis, Patricia
Sievers, Annette
McCarty, Douglas M.
Somanathan, Suryanarayan
Pan, Clark
Bell, Robert D.
MOLECULAR THERAPY, 2021, 29 (04) : 251 - 251
[10] Results from First-in-Human Clinical Trial of RP-A501 (AAV9:LAMP2B) Gene Therapy Treatment for Danon Disease
Greenberg, Barry
Eshraghian, Emily
Battiprolu, Pavan
Ricks, David
Yarabe, Paul
Schwartz, Jonathan
Patel, Kinnari
Shah, Guarav
Trevejo, Jose
CIRCULATION, 2021, 144

← 1 2 3 4 5 →